Validation of Monosaccharide Composition Assay Using HPLC‐UV Platform for Monoclonal Antibody Products in Compliance with ICH Guideline
Log in with Open Athens, Shibboleth, or your institutional credentials.
If you have previously obtained access with your personal account, Please log in.
If you previously purchased this article, Log in to Readcube.
You previously purchased this article on READCUBE_PURCHASE_DATE. Click on an option below to access.
Logged in as READCUBE_USER. Log out of ReadCube.
Abstract
Monoclonal antibodies (mAbs) are the largest class of glycosylated biopharmaceuticals. Glycans are a key functional component of mAbs, and thus their characterization is highly required during mAb developmental and regulatory phases. In particular, monosaccharides are crucial for antibody efficacy, safety, cytotoxicity, and potency, so reliable monosaccharide composition assay (MCA) is required for quality control (QC) testing. Traditional methods for MCA such as HPAE‐PAD and HPLC‐FLD have been suffering from low sensitivity and poor reproducibility. In this study, we developed an alternative QC method for MCA of mAb with 1‐Phenyl‐3‐methyl‐5‐pyrazolone (PMP) tag products using HPLC‐UV platform equipped in most QC laboratories. Four characteristics including specificity, linearity, precision, and accuracy were systemically evaluated according to ICH Q2(R1) guideline. Inter‐laboratory studies were also performed to validate method reproducibility and reliability. It will be a powerful platform for QC test of not only mAb products but also Fc fusion glycoprotein products.
